In a statement to reporters on Wednesday, an AstraZeneca spokesperson, Michele Meixell, said that the individual did not have a confirmed case of transverse myelitis. Those tests will be delivered to an independent safety committee that will review the event and establish a final diagnosis.”The company did not respond to a request for clarification about whether transverse myelitis was suspected. Transverse myelitis is relatively rare, sparking symptoms in roughly 1,400 people each year in the United States, according to the National Institutes of Health. There has been some past speculation that vaccines might be able to trigger transverse myelitis, she added. Both transverse myelitis and Guillain-Barre syndrome have been pinpointed as possible complications of Covid-19.

Source: New York Times September 10, 2020 10:37 UTC